<p>1970 年 1 月 1 日- 上午 12:00</p>
<ul>
<li><em>这些协议旨在提供灵活的融资解决方案，以支持运营，同时完成战略合作伙伴关系</em></li>
<li><em>公司正在与潜在合作伙伴的战略交易的最终阶段，预计将在年底前完成交易</em></li>
<li><em>这些协议确保 BioAtla 在完成该过程的同时能够保持运营势头</em></li>
</ul>
<p>圣地亚哥，2025 年 11 月 21 日（GLOBE NEWSWIRE）-- <strong>BioAtla, Inc. (纳斯达克：BCAB)</strong>，一家全球临床阶段生物技术公司，专注于开发条件性活性生物制剂（CAB）抗体疗法用于治疗实体肿瘤，今天宣布已与 Yorkville Advisors Global（Yorkville）的一个附属公司及 Anson Advisors Inc.管理的基金签署了预付预付款协议，为公司提供总计 750 万美元的预付款。BioAtla 还签署了一项备用股权购买协议，Yorkville 承诺在公司行使其选择权时，最多以低于当前市场价格 3% 的折扣购买总计 1500 万美元的普通股，期限为三年，需遵循某些条件。</p>
<p>“这些协议为我们提供了财务灵活性，并确保 BioAtla 在努力完成我们相信将为 BioAtla 及其股东解锁重大价值的战略合作伙伴关系时能够保持运营势头，” BioAtla 的董事长、首席执行官兼联合创始人 Jay M. Short 博士表示。“我们仍然按计划在年底前完成这一交易。”</p>
<p>预付预付款的关键条款包括以面值的 95% 购买 750 万美元，实际收到的总收入为 712.5 万美元。该预付款的利率为 4%，可以以现金偿还或根据转换价格转换为普通股，转换价格为 1.39 美元或交易日回溯期内最低日均成交价的 95% 中的较低者。交易日回溯期将不早于 2025 年 11 月 18 日开始。</p>
<p>Tungsten Advisors 担任这些协议的唯一配售代理。</p>
<p>有关协议的更详细描述可以在 BioAtla 向美国证券交易委员会（“SEC”）提交的 8-K 表格中找到。</p>
<p><strong>法律声明</strong></p>
<p>根据 BioAtla 在 2023 年 1 月 6 日向 SEC 提交的有效货架注册声明（表格 S-3，文件编号 333-269148），以及于 2023 年 1 月 17 日被宣布生效，预付预付款协议和备用股权购买协议下可发行的股份正在由 BioAtla 提供。与该发行相关并描述条款的招股说明书补充将提交给 SEC，并将在 SEC 网站 www.sec.gov 上提供。当可用时，招股说明书补充及其附带的招股说明书的电子副本也可以从 Tungsten Advisors 获取，地址为纽约市第三大道 767 号，29 楼，邮政编码 10017，电话（917）268-1097，或通过电子邮件联系 prospectus@tungstenadv.com。</p>
<p>本新闻稿不构成对出售或购买根据任何协议提供的证券的要约或招揽，也不应在任何州或其他司法管辖区进行这些证券的销售，除非在任何此类州或其他司法管辖区的证券法下注册或合格之前。</p>
<p><strong>关于 BioAtla</strong> <strong>®</strong> <strong>, Inc.</strong></p>
<p>BioAtla 是一家全球临床阶段生物技术公司，在加利福尼亚州圣地亚哥和中国北京通过与 BioDuro-Sundia 的合同关系开展业务，后者提供临床前开发服务。利用其专有的 CAB 平台技术，BioAtla 开发新型可逆活性单克隆和双特异性抗体及其他蛋白质治疗产品候选者。CAB 产品候选者旨在具有更选择性的靶向、更高的疗效和更低的毒性，以及比传统抗体更具成本效益和可预测的生产。BioAtla 在其 CAB 平台技术和产品方面拥有广泛的全球专利覆盖，活跃的专利事项超过 780 项，其中超过 500 项为已授予专利。所有主要市场的广泛专利覆盖包括制造、筛选和生产 CAB 产品候选者的方法，以及特定产品的物质组成覆盖。要了解更多关于 BioAtla, Inc.的信息，请访问 www.bioatla.com。</p>
<p><strong>关于 Ozuriftamab Vedotin (Oz-V)</strong></p>
<p>Ozuriftamab vedotin (Oz-V)，CAB-Platform-ROR2-ADC，是一种针对 ROR2 的条件性和可逆活性抗体药物偶联物，ROR2 是一种跨膜受体酪氨酸激酶，存在于许多不同的实体肿瘤中，包括头颈癌、肺癌、三阴性乳腺癌和黑色素瘤。ROR2 的过表达是由与 HPV 感染相关的癌蛋白驱动的，形成与不良预后和对化疗及免疫疗法耐药相关的癌症轴。这一准备进入第三阶段的临床资产针对多种实体肿瘤适应症，包括治疗在 PD-1/L1 疗法和铂类化疗中经历过进展的 OPSCC 患者。FDA 已授予 ozuriftamab vedotin 用于治疗复发或转移性 SCCHN 患者的快速通道资格。</p>
<p><strong>关于 CAB-EpCAM x CAB-CD3 双特异性 T 细胞激活抗体</strong></p>
<p>BioAtla 正在开发 BA3182 作为一种潜在的抗癌疗法，针对晚期腺癌患者。BA3182 是一种（CAB）EpCAM x（CAB）CD3 双特异性 T 细胞结合抗体，包含两个针对 EpCAM 的结合位点和两个针对 CD3ε的结合位点。EpCAM 和 CD3ε的结合位点被设计为在肿瘤微环境（TME）中特异性和可逆地结合各自的靶标，并在 TME 外部减少结合。CAB 对 CAB EpCAM 和 CAB CD3ε两个臂的选择性结合是激活 T 细胞与肿瘤结合所必需的，从而实现双特异性抗体中每个 CAB 结合臂的组合选择性。BioAtla 继续推进正在进行的第一阶段研究，以评估 BA3182 在晚期腺癌患者中的安全性、药代动力学和疗效。</p>
<p><strong>前瞻性声明</strong> 本新闻稿中的声明包含 “前瞻性声明”，这些声明面临重大风险和不确定性。新闻稿中包含的前瞻性声明可以通过使用诸如 “预期”、“期望”、“相信”、“将”、“可能”、“应该”、“估计”、“项目”、“展望”、“预测” 或其他类似词汇来识别。前瞻性声明的示例包括我们关于 BioAtla 的商业计划和前景的声明；以及我们战略合作伙伴关系和交易的预期时间、收益和结果。前瞻性声明基于 BioAtla 当前的预期，并受到固有的不确定性、风险和假设的影响，其中许多超出我们的控制，难以预测，可能导致实际结果与我们的预期有重大差异。此外，某些前瞻性声明基于对未来事件的假设，这些假设可能并不准确。可能导致实际结果不同的因素包括：对我们作为持续经营能力的能力产生重大怀疑的因素，以及我们需要额外资金以继续开发我们的 CAB 技术平台和 CAB 产品候选者的风险；初步或中期临床结果可能不代表后续队列或更大人群的结果的风险；临床和前临床试验的潜在延迟；研究和开发中固有的不确定性，包括满足预期临床终点的能力、临床试验的开始和/或完成日期、监管提交日期或监管批准日期，以及不利的新临床数据和对现有临床数据的进一步分析的可能性；监管机构是否会对临床研究的设计和结果感到满意，或根据临床研究的结果采取有利的监管行动；我们对 CAB 技术平台成功的依赖；我们在进行和未来临床试验中招募患者的能力；成功选择和优先考虑资产以专注于选定产品候选者和适应症的能力；我们与第三方建立合作和伙伴关系的能力以及这些合作和伙伴关系的成功；我们对第三方在临床试验中制造和供应我们的产品候选者的依赖；我们对第三方进行我们的临床试验和一些研究及前临床测试的依赖；由于超出我们控制的地缘政治或宏观经济事件（包括健康流行病或大流行）可能产生的不利影响；以及在我们于 2025 年 3 月 27 日向 SEC 提交的 10-K 表格年报中 “风险因素” 部分描述的其他风险和不确定性。新闻稿中包含的前瞻性声明截至本日期作出，BioAtla 没有义务更新该信息，除非适用法律要求。</p>
<p><strong>内部联系人：</strong></p>
<p>Richard Waldron</p>
<p>首席财务官</p>
<p>BioAtla, Inc.</p>
<p>rwaldron@bioatla.com</p>
<p>858.356.8945</p>
<p><strong>外部联系人：</strong></p>
<p>Joyce Allaire</p>
<p>LifeSci Advisors, LLC</p>
<p>jallaire@lifesciadvisors.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNE1ERTVNeU0zTWpjMk56VTVJekl4T1RBeE16VT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNE1ERTVNeU0zTWpjMk56VTVJekl4T1RBeE16VT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDkzNGJjMGUtOWExYS00Y2YzLTgyMzQtNTM4MzhlM2MyM2Q4LTEyMDE2ODgtMjAyNS0xMS0yMS1lbg==/tiny/BioAtla-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDkzNGJjMGUtOWExYS00Y2YzLTgyMzQtNTM4MzhlM2MyM2Q4LTEyMDE2ODgtMjAyNS0xMS0yMS1lbg==/tiny/BioAtla-Inc-.png"/></p>

BCAB

<p>BioAtla, Inc. 已签署最高达 2250 万美元的灵活融资协议，以支持运营，同时完成战略合作伙伴关系。这些协议包括 750 万美元的预付款和 1500 万美元的备用股权购买协议。这些资金将有助于维持公司的运营势头，因为公司计划在年底前完成战略交易</p>

<p>01/01/1970 - 12:00 AM</p>
<div class="lb-trans"><p>1970 年 1 月 1 日- 上午 12:00</p>
</div><ul>
<li><em>These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership</em></li>
<li><em>Company is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to complete the transaction by year end</em></li>
<li><em>These agreements ensure BioAtla can maintain operational momentum while completing that process</em></li>
</ul>
<div class="lb-trans"><ul>
<li><em>这些协议旨在提供灵活的融资解决方案，以支持运营，同时完成战略合作伙伴关系</em></li>
<li><em>公司正在与潜在合作伙伴的战略交易的最终阶段，预计将在年底前完成交易</em></li>
<li><em>这些协议确保 BioAtla 在完成该过程的同时能够保持运营势头</em></li>
</ul>
</div><p>SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- <strong>BioAtla, Inc. (Nasdaq: BCAB)</strong>, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into Pre-paid Advance Agreements with an affiliate of Yorkville Advisors Global (Yorkville) and funds managed by of Anson Advisors Inc. to provide an aggregate $7.5 million advance to the Company. BioAtla also entered into a Standby Equity Purchase Agreement in which Yorkville has a commitment to buy, if the Company exercises its option, for up to a total of $15 million of common stock at a 3% discount to the then current market prices over three years, subject to certain conditions.</p>
<div class="lb-trans"><p>圣地亚哥，2025 年 11 月 21 日（GLOBE NEWSWIRE）-- <strong>BioAtla, Inc. (纳斯达克：BCAB)</strong>，一家全球临床阶段生物技术公司，专注于开发条件性活性生物制剂（CAB）抗体疗法用于治疗实体肿瘤，今天宣布已与 Yorkville Advisors Global（Yorkville）的一个附属公司及 Anson Advisors Inc.管理的基金签署了预付预付款协议，为公司提供总计 750 万美元的预付款。BioAtla 还签署了一项备用股权购买协议，Yorkville 承诺在公司行使其选择权时，最多以低于当前市场价格 3% 的折扣购买总计 1500 万美元的普通股，期限为三年，需遵循某些条件。</p>
</div><p>“These agreements provide us with financial flexibility and ensure BioAtla can maintain operational momentum as we work to finalize a strategic partnership that we believe will unlock significant value for BioAtla and our shareholders,” said Jay M. Short, Ph.D., Chairman, CEO and co-founder of BioAtla. “We remain on-track to complete this transaction by year end.”</p>
<div class="lb-trans"><p>“这些协议为我们提供了财务灵活性，并确保 BioAtla 在努力完成我们相信将为 BioAtla 及其股东解锁重大价值的战略合作伙伴关系时能够保持运营势头，” BioAtla 的董事长、首席执行官兼联合创始人 Jay M. Short 博士表示。“我们仍然按计划在年底前完成这一交易。”</p>
</div><p>Key terms of the pre-paid advance include $7.5 million purchased at 95% of face value for $7.125 million gross proceeds received at closing. This advance accrues interest at 4% and may be repaid in cash or converted into common stock based on a conversion price equal to the lower of $1.39 or 95% of the lowest daily VWAP over trading day look back period. The trading day look back period will begin no earlier than November 18, 2025.</p>
<div class="lb-trans"><p>预付预付款的关键条款包括以面值的 95% 购买 750 万美元，实际收到的总收入为 712.5 万美元。该预付款的利率为 4%，可以以现金偿还或根据转换价格转换为普通股，转换价格为 1.39 美元或交易日回溯期内最低日均成交价的 95% 中的较低者。交易日回溯期将不早于 2025 年 11 月 18 日开始。</p>
</div><p>Tungsten Advisors acted as the sole placement agent for these agreements.</p>
<div class="lb-trans"><p>Tungsten Advisors 担任这些协议的唯一配售代理。</p>
</div><p>A more detailed description of the agreements can be found in BioAtla’s Form 8-K filed with the U.S Securities and Exchange Commission (the “SEC”).</p>
<div class="lb-trans"><p>有关协议的更详细描述可以在 BioAtla 向美国证券交易委员会（“SEC”）提交的 8-K 表格中找到。</p>
</div><p><strong>Legal Notice</strong></p>
<div class="lb-trans"><p><strong>法律声明</strong></p>
</div><p>The shares issuable under the Pre-Paid Advance Agreement and the Standby Equity Purchase Agreement are being offered by BioAtla pursuant to an effective shelf registration statement on Form S-3 (File No. 333-269148) previously filed with the SEC on January 6, 2023 and was declared effective on January 17, 2023. A prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, electronic copies of the prospectus supplement and the accompanying prospectus may also be obtained from Tungsten Advisors, 767 Third Ave, 29th Floor, New York, NY 10017, by phone at (917) 268-1097 or email at prospectus@tungstenadv.com.</p>
<div class="lb-trans"><p>根据 BioAtla 在 2023 年 1 月 6 日向 SEC 提交的有效货架注册声明（表格 S-3，文件编号 333-269148），以及于 2023 年 1 月 17 日被宣布生效，预付预付款协议和备用股权购买协议下可发行的股份正在由 BioAtla 提供。与该发行相关并描述条款的招股说明书补充将提交给 SEC，并将在 SEC 网站 www.sec.gov 上提供。当可用时，招股说明书补充及其附带的招股说明书的电子副本也可以从 Tungsten Advisors 获取，地址为纽约市第三大道 767 号，29 楼，邮政编码 10017，电话（917）268-1097，或通过电子邮件联系 prospectus@tungstenadv.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities offered under either agreement, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成对出售或购买根据任何协议提供的证券的要约或招揽，也不应在任何州或其他司法管辖区进行这些证券的销售，除非在任何此类州或其他司法管辖区的证券法下注册或合格之前。</p>
</div><p><strong>About BioAtla</strong> <strong>®</strong> <strong>, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 BioAtla</strong> <strong>®</strong> <strong>, Inc.</strong></p>
</div><p>BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. To learn more about BioAtla, Inc., visitwww.bioatla.com.</p>
<div class="lb-trans"><p>BioAtla 是一家全球临床阶段生物技术公司，在加利福尼亚州圣地亚哥和中国北京通过与 BioDuro-Sundia 的合同关系开展业务，后者提供临床前开发服务。利用其专有的 CAB 平台技术，BioAtla 开发新型可逆活性单克隆和双特异性抗体及其他蛋白质治疗产品候选者。CAB 产品候选者旨在具有更选择性的靶向、更高的疗效和更低的毒性，以及比传统抗体更具成本效益和可预测的生产。BioAtla 在其 CAB 平台技术和产品方面拥有广泛的全球专利覆盖，活跃的专利事项超过 780 项，其中超过 500 项为已授予专利。所有主要市场的广泛专利覆盖包括制造、筛选和生产 CAB 产品候选者的方法，以及特定产品的物质组成覆盖。要了解更多关于 BioAtla, Inc.的信息，请访问 www.bioatla.com。</p>
</div><p><strong>About Ozuriftamab Vedotin (Oz-V)</strong></p>
<div class="lb-trans"><p><strong>关于 Ozuriftamab Vedotin (Oz-V)</strong></p>
</div><p>Ozuriftamab vedotin (Oz-V), CAB-Platform-ROR2-ADC, is a conditionally and reversibly active antibody drug conjugate directed against ROR2, a transmembrane receptor tyrosine kinase that is present across many different solid tumors including head and neck, lung, triple-negative breast cancer and melanoma. Overexpression of ROR2, a noncanonical wnt5A signaling receptor, is driven by oncoproteins associated with HPV infection and forms a cancer axis that is associated with poor prognosis and resistance to chemo- and immunotherapies. This Phase 3 ready clinical asset is targeting multiple solid tumor indications, including the treatment of patients with OPSCC who have previously experienced progression on PD-1/L1 therapies and platinum chemotherapy. The FDA granted Fast Track Designation to ozuriftamab vedotin for the treatment of patients with recurrent or metastatic SCCHN.</p>
<div class="lb-trans"><p>Ozuriftamab vedotin (Oz-V)，CAB-Platform-ROR2-ADC，是一种针对 ROR2 的条件性和可逆活性抗体药物偶联物，ROR2 是一种跨膜受体酪氨酸激酶，存在于许多不同的实体肿瘤中，包括头颈癌、肺癌、三阴性乳腺癌和黑色素瘤。ROR2 的过表达是由与 HPV 感染相关的癌蛋白驱动的，形成与不良预后和对化疗及免疫疗法耐药相关的癌症轴。这一准备进入第三阶段的临床资产针对多种实体肿瘤适应症，包括治疗在 PD-1/L1 疗法和铂类化疗中经历过进展的 OPSCC 患者。FDA 已授予 ozuriftamab vedotin 用于治疗复发或转移性 SCCHN 患者的快速通道资格。</p>
</div><p><strong>About CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager Antibody</strong></p>
<div class="lb-trans"><p><strong>关于 CAB-EpCAM x CAB-CD3 双特异性 T 细胞激活抗体</strong></p>
</div><p>BioAtla is developing BA3182 as a potential anticancer therapy for patients with advanced adenocarcinoma. BA3182 is a (CAB) EpCAM x (CAB) CD3 bispecific T cell engager antibody that contains two binding sites for EpCAM and two binding sites for CD3ε. The binding sites for EpCAM and CD3ε have been designed to bind their respective targets specifically and reversibly under the conditions found in the TME and to have reduced binding outside of the TME. The CAB selective binding to both the CAB EpCAM and CAB CD3ε arms are required to activate the T cell engagement against the tumor, thus enabling the combined selectivity of each CAB binding arm in the bispecific antibody. BioAtla continues to advance the ongoing Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of BA3182 in advanced adenocarcinoma patients.</p>
<div class="lb-trans"><p>BioAtla 正在开发 BA3182 作为一种潜在的抗癌疗法，针对晚期腺癌患者。BA3182 是一种（CAB）EpCAM x（CAB）CD3 双特异性 T 细胞结合抗体，包含两个针对 EpCAM 的结合位点和两个针对 CD3ε的结合位点。EpCAM 和 CD3ε的结合位点被设计为在肿瘤微环境（TME）中特异性和可逆地结合各自的靶标，并在 TME 外部减少结合。CAB 对 CAB EpCAM 和 CAB CD3ε两个臂的选择性结合是激活 T 细胞与肿瘤结合所必需的，从而实现双特异性抗体中每个 CAB 结合臂的组合选择性。BioAtla 继续推进正在进行的第一阶段研究，以评估 BA3182 在晚期腺癌患者中的安全性、药代动力学和疗效。</p>
</div><p><strong>Forward-looking Statements</strong> Statements in this press release contain &#34;forward-looking statements&#34; that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as &#34;anticipate,&#34; &#34;expect,&#34; &#34;believe,&#34; &#34;will,&#34; &#34;may,&#34; &#34;should,&#34; &#34;estimate,&#34; &#34;project,&#34; &#34;outlook,&#34; &#34;forecast&#34; or other similar words. Examples of forward-looking statements include, among others, statements we make regarding BioAtla’s business plans and prospects; and the expected timing, benefits and outcomes of our strategic partnerships and transactions. Forward-looking statements are based on BioAtla's current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: factors that raise substantial doubt about our ability to continue as a going concern and that we will need additional funding to continue development of our CAB technology platform and our CAB product candidates; the risk that preliminary or interim clinical results may not be indicative of results from later cohorts or larger populations; potential delays in clinical and preclinical trials; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, or regulatory approval dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether regulatory authorities will be satisfied with the design of and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies; our dependence on the success of our CAB technology platform; our ability to enroll patients in our ongoing and future clinical trials; the successful selection and prioritization of assets to focus development on selected product candidates and indications; our ability to form collaborations and partnerships with third parties and the success of such collaborations and partnerships; our reliance on third parties for the manufacture and supply of our product candidates for clinical trials; our reliance on third parties to conduct our clinical trials and some aspects of our research and preclinical testing; potential adverse impacts due to geopolitical or macroeconomic events outside of our control, including health epidemics or pandemics; and those other risks and uncertainties described in the section titled &#34;Risk Factors&#34; in our Annual Report on Form 10-K filed with the SEC on March 27, 2025, our Quarterly Reports on Form 10-Q filed with the SEC on May 6, 2025, August 7, 2025 and November 13, 2025 and our subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and BioAtla undertakes no duty to update such information except as required under applicable laws.</p>
<div class="lb-trans"><p><strong>前瞻性声明</strong> 本新闻稿中的声明包含 “前瞻性声明”，这些声明面临重大风险和不确定性。新闻稿中包含的前瞻性声明可以通过使用诸如 “预期”、“期望”、“相信”、“将”、“可能”、“应该”、“估计”、“项目”、“展望”、“预测” 或其他类似词汇来识别。前瞻性声明的示例包括我们关于 BioAtla 的商业计划和前景的声明；以及我们战略合作伙伴关系和交易的预期时间、收益和结果。前瞻性声明基于 BioAtla 当前的预期，并受到固有的不确定性、风险和假设的影响，其中许多超出我们的控制，难以预测，可能导致实际结果与我们的预期有重大差异。此外，某些前瞻性声明基于对未来事件的假设，这些假设可能并不准确。可能导致实际结果不同的因素包括：对我们作为持续经营能力的能力产生重大怀疑的因素，以及我们需要额外资金以继续开发我们的 CAB 技术平台和 CAB 产品候选者的风险；初步或中期临床结果可能不代表后续队列或更大人群的结果的风险；临床和前临床试验的潜在延迟；研究和开发中固有的不确定性，包括满足预期临床终点的能力、临床试验的开始和/或完成日期、监管提交日期或监管批准日期，以及不利的新临床数据和对现有临床数据的进一步分析的可能性；监管机构是否会对临床研究的设计和结果感到满意，或根据临床研究的结果采取有利的监管行动；我们对 CAB 技术平台成功的依赖；我们在进行和未来临床试验中招募患者的能力；成功选择和优先考虑资产以专注于选定产品候选者和适应症的能力；我们与第三方建立合作和伙伴关系的能力以及这些合作和伙伴关系的成功；我们对第三方在临床试验中制造和供应我们的产品候选者的依赖；我们对第三方进行我们的临床试验和一些研究及前临床测试的依赖；由于超出我们控制的地缘政治或宏观经济事件（包括健康流行病或大流行）可能产生的不利影响；以及在我们于 2025 年 3 月 27 日向 SEC 提交的 10-K 表格年报中 “风险因素” 部分描述的其他风险和不确定性。新闻稿中包含的前瞻性声明截至本日期作出，BioAtla 没有义务更新该信息，除非适用法律要求。</p>
</div><p><strong>Internal Contact:</strong></p>
<div class="lb-trans"><p><strong>内部联系人：</strong></p>
</div><p>Richard Waldron</p>
<div class="lb-trans"><p>Richard Waldron</p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官</p>
</div><p>BioAtla, Inc.</p>
<div class="lb-trans"><p>BioAtla, Inc.</p>
</div><p>rwaldron@bioatla.com</p>
<div class="lb-trans"><p>rwaldron@bioatla.com</p>
</div><p>858.356.8945</p>
<div class="lb-trans"><p>858.356.8945</p>
</div><p><strong>External Contact:</strong></p>
<div class="lb-trans"><p><strong>外部联系人：</strong></p>
</div><p>Joyce Allaire</p>
<div class="lb-trans"><p>Joyce Allaire</p>
</div><p>LifeSci Advisors, LLC</p>
<div class="lb-trans"><p>LifeSci Advisors, LLC</p>
</div><p>jallaire@lifesciadvisors.com</p>
<div class="lb-trans"><p>jallaire@lifesciadvisors.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNE1ERTVNeU0zTWpjMk56VTVJekl4T1RBeE16VT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU4MDE5MyM3Mjc2NzU5IzIxOTAxMzU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDkzNGJjMGUtOWExYS00Y2YzLTgyMzQtNTM4MzhlM2MyM2Q4LTEyMDE2ODgtMjAyNS0xMS0yMS1lbg==/tiny/BioAtla-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MDkzNGJjMGUtOWExYS00Y2YzLTgyMzQtNTM4MzhlM2MyM2Q4LTEyMDE2ODgtMjAyNS0xMS0yMS1lbg==/tiny/BioAtla-Inc-.png"/></p>

BioAtla 签署协议，获得高达 2250 万美元的灵活融资 | BCAB 股票新闻